Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape

Cancer Immunology, Immunotherapy

Volumn 55, Issue 1, 2006, Pages 1-22

  Egorov, Igor K ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

Cancer; Immune escape; Macrophages; MHC; Somatic mosaicism; T cells

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTING CELL; CELL SUBPOPULATION; CONGENIC STRAIN; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; TUMOR CELL; TUMOR ESCAPE; TUMOR IMMUNITY;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENES, MHC CLASS I; GENES, MHC CLASS II; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LYMPHOMA; MACROPHAGES; MOSAICISM; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; NEOPLASMS; SARCOMA; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 28944434970     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0007-8     Document Type: Review

References (140)

1. Ha PK, Benoit NE, Yochem R, Sciubba J, Zahurak M, Sidransky D, Pevsner J, Westra WH, Califano J (2003) A transcriptional progression model for head and neck cancer. Clin Cancer Res 9:3058-3064
2. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61:1569-1577
3. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811-816
4. Lee YF, John M, Falconer A, Edwards S, Clark J, Flohr P, Roe T, Wang R, Shipley J, Grimer RJ, Mangham DC, Thomas JM, Fisher C, Judson I, Cooper CS (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201-7204
5. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vogeli TA, Grimm MO (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10:3410-3421
6. Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K, Matsunaga A, Komuro K, Kanai M, Kawakami A, Fujiwara Y, Kobayashi N, Shirata K, Nishimura N, Okushiba S, Kondo S, Hamada J, Yoshiki T, Moriuchi T, Katoh H (2004) Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res 10:3629-3638
7. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 3:1-13
8. Nanda NK, Sercarz EE (1995) Induction of anti-self immunity to cure cancer. Cell 82:13-17
9. Overwijk WW, Restifo NP (2000) Autoimmunity and the immunotherapy of cancer: targeting the self to destroy the other. Crit Rev Immunol 20:433
10. Zorn E, Hercend T (1999) A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 29(2):592-601
11. Echchakir H, Dorothée G, Vergnon I, Menez J, Chouaib S, and Mami-Chouaib F (2002) Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci USA 99:9358-9363
12. Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tuting T, Kaczmarek E, Deleo AB (2005) Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer 113:961-970
13. Prehn R, Main D (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:768-798
14. Van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51-94
15. Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M, Sumimoto H (2004) Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95:784-791
16. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182
17. Adam JK, Odhav B, Bhoola KD (2003) Immune responses in cancer. Pharmacol Ther 99:113-132
18. Simpson E (2004) Immunotherapy and gene therapy. IDrugs 7:105-108
19. Turtle CJ, Hart DN (2004) Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets 5:17-39
20. Komenaka I, Hoerig H, Kaufman HL (2004) Immunotherapy for melanoma. Clin Dermatol 22:251-265
21. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91:1183-1190
22. Zorn E, Hercend T (1999) A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 29(2):592-601
23. Livingston P (2001) The unfulfilled promise of melanoma vaccines. Clin Cancer Res 7:1837-1838
24. Garcia-Lora A, Algarra I, Collado A (2003) Tumor immunogenecity, vaccination and escape strategies. Eur J Immunogenet 30:177-183
25. Amad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844-854
26. Anichini A, Vegetti C, Mortarini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855-864
27. Atanackovic D, Block A, de Weerth A, Faltz C, Hossfeld DK, Hegewisch-Becker S (2004) Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res 10:2600-2608
28. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448-456
29. Pawelec G (2004) Immunotherapy and immunoselection - tumour escape as the final hurdle. FEBS Lett 567:63-66
30. Pawelec G (2004) Tumour escape from the immune response. Cancer Immunol Immunother 53(10):843
31. Ostrand-Rosenberg S (2004) Introductory comments to symposium in writing: inhibitors of immunosurveillence and anti-tumor immunity. Cancer Immunol Immunother 53:63-91
32. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64:2865-2873
33. Loeb LA, Loeb KR, Anderson JP (2003) Multiple mutations and cancer. Proc Natl Acad Sci USA 100:776-781
34. Pilch H, Hohn H, Neukirch C, Freitag K, Knapstein PG, Tanner B, Maeurer MJ (2002) Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Clin Diagn Lab Immunol 9:267-278
35. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005
36. Khong HT, Wang QJ, Rosenberg SA (2004) Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 27:184-190
37. Abrams SI (2005) Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front Biosci 10:809-821
38. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
39. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
40. Benchetritt F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH, Tartour E (2003) Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy. Bull Cancer 90:677-685
41. Britten CM, Mueller L, Knights A, Pawelec G (2004) Meeting report: cancer immunotherapy 2004, 6-7 May 2004, Mainz, Germany. Cancer Immunol Immunother 53:1153-1158
42. Strickberger MW (2000) Evolution, 3rd edn. Jones and Bartlett Publishers, Sudbury
43. McClelland EE, Penn DJ, Potts WK (2003) Major histocompatibility complex heterozygote superiority during coinfection. Infect Immunity 71:2079-2086
44. Egorov OS, Sargent E, Carlson GA, Egorov IK (1990) Mouse mutants affecting growth and metastasis of a syngeneic tumor. In: Egorov IK, David CS (eds) Transgenic mice and mutants in MHC research. Springer, Berlin Heidelberg New York, pp 276-281
45. Egorov OS, Liu Y, Sargent EE, Drizlikh GI, Egorov IK (1992) Screening mouse mutations for resistance to cancer metastasis. Immunogenetics 36:219-233
46. d major histocompatibility complex haplotype. Proc Natl Acad Sci USA 88:9243-9247
47. Miyazawa M, Nishio J, Wehrly K, David CS, Chesebro B (1992) Spontaneous recovery from Friend retrovirus-induced leukemia. Mapping of the Rfv-2 gene in the Q/TL region of the mouse MHC. J Immunol 148:1964-1967
48. Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong C (2003) Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci USA 100:6682-6687
49. Liu Y, McMinimy DL, Savinov AY, Johnson KA, Kremlev SG, Chapoval AI, Egorov IK (2001) Hidden variables: unstable Aβ chain genes encoding antigen recognition structures in tumor survivors. Mol Immunol 37:1091-1110
50. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512-518
51. Egorov IK (1967) A mutation of the histocompatibility-2 locus in the mouse. Genetika 3:136-144
52. d genes expressed in the dm1 mutant. Proc Natl Acad Sci USA 81:5204-5208
53. Sun YH, Goodenow RS, Hood L (1985) Molecular basis of the dm1 mutation in the major histocompatibility complex of the mouse: a D/L hybrid gene. J Exp Med 162:1588-1602
54. Lie WR, Myers NB, Connolly JM, Gorka J, Lee DR, Hansen TH (1991) The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure. J Exp Med 173:449-459
55. Blankenstein T (2004) The role of inflammation in tumor growth and tumor suppression. Novartis Found Symp 256:205-210
56. b mRNA in mutant mouse S-27 resisting cancer metastasis and affecting responses to tuberculosis. Mol Immunol 30:1057-1060
57. Sanchez F, Radaeva TV, Nikonenko BV, Persson A-S, Sengul S, Schalling M, Schurr E, Apt AS, Lavebratt C (2003) Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice. Infect Immun 71:126-131
58. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV (2003) Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 171:175-184
59. Albert SE, Shelton K, Sun MJ, Nelson EG (1991) Analysis of the cDNA sequence encoding MHC-Aβ in tubular epithelium from mouse kidney. Kidney Int 40:139-142
60. Rees RC, Mian S (1999) Selective MHC expression in tumors modulates adaptive and innate antitumor responses. Cancer Immunol Immunother 48:374-381
61. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904-910
62. Bubenik J (2004) MHC class I down-regulation: tumor escape from immune response? Int J Oncol 25:487-491
63. Guinn B (2005) Meeting report. In: Immunotherapy at the American Association for Cancer Research 95th annual meeting: a personal impression. Cancer Immunol Immunother 54(3):290-295. DOI: 10.1007/s00262-004-0586-9
64. Cui Z, Willingham MC (2004) The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother 53:473-478
65. Gorer PA, Lyman S, Snell GD (1948) Studies on the genetic and antigenic basis of tumor transplantation; linkage between a histocompatibility gene and 'fused' in mice. Proc Roy Soc B 135:499-505
66. Parham P (ed) (1999) Genomic organization of MHC: structure, origins and function. Immunol Rev 167:1-379
67. Snell GD, Dausset J, Nathenson S (1976) Histocompatibility. Academic, New York
68. Hui KM, Bidwell JL (eds) (1993) Handbook of HLA typing techniques. CRC Press, Boka Raton
69. Fairchild PJ (1998) Presentation of antigenic peptides by products of the major histocompatibility complex. J Peptide Sci 4:182-194
70. Stevanovic S, Lemmel C, Hantschel M, Eberle U (2003) Generating data for databases - the peptide repertoire of HLA molecules. Novartis Found Symp 254:143-155
71. Schafroth HD and Floudas CA (2004) Predicting peptide binding to MHC pockets via molecular modeling, implicit solvation, and global optimization. Proteins 54:534-556
72. Parham P (1989) Getting into the groove. Nature 342:617-618
73. b at 2.4 Å resolution: implications for antigen-determinant selection. Cell 76:39-50
74. Murray JS, Fois SD, Schountz T, Ford SR, Tawde MD, Brown JC, Siahaan TJ (2002) Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions. J Pept Res 59:115-122
75. Macdonald WA, Purcell AW, Mifsud NA, Ely LK, Williams DS, Chang L, Gorman JJ, Clements CS, Kjer-Nelsen L, Koelle DM, Burrows SR, Tait BD, Holdsworth R, Brooks AG, Lovrecz GO, Lu L, Rossjohn J, McCluskey J (2003) A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 198:679-691
76. Klein J (1986) Natural history of the major histocompatibility complex. Wiley, New York
77. Abele R, Tampe R (2004) The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 19:216-224
78. Admon A, Barnea E, Ziv T (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2:388-398
79. Hickman HD, Luis AD, Buchli R, Few SR, Sathiamurthy M, VanGundy RS, Giberson CF, Hildebrand WH (2004) Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 172:2944-2952
80. Krüger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, Weinschenk T, Müller M, Hennenlotter J, Stenzl A, Rammenseel H-G and Stevanovi S (2004) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (Online) DOI: 10.1007/s00262-004-0650-5
81. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non-dominant anchor residues. J Exp Med 180:1471-1483
82. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J et al (1994) The relationship between class I binding affinity and immunogenicity of potential cyotoxic T cell epitopes. J Immunol 153:5586-5592
83. da Silva J (2003) The evolutionary adaptation of HIV-1 to specific immunity. Curr HIV Res 1:363-371
84. Villadangos JA (2001) Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 38:329-346
85. Jerne NK (1971) The somatic generation of immune recognition. Eur J Immunol 1:1-9
86. Slager EH (2004) Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol 172:5095-102
87. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-221
88. k in complex with a dominant epitope of lysozyme. Immunity 8:305-317
89. Zhu Y, Rudensky AY, Corper AL, Teyton L (2003) Wilson IA Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. J Mol Biol 326:1157-1174
90. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622-627
91. O'Sallivan D, Sidney J, Appella E, Walker L, Phillips L, Colon SM, Miles C, Chesnut RW, Sette A (1990) Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 145:1799-1808
92. Boehncke W-H, Takeshita T, Pendelton CD, Sadegh-Nasseri S, Racioppi L, Houghten RA, Berzofsky JA, Germain RN (1993) The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol 150:331-341
93. Salmon M (1992) The immunogenetic component of susceptibility to rheumatoid arthritis. Curr Opin Rheumatol 4:342-347
94. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A, Bell JI, Srominger JL, Jones EY, Fugger L (2004) Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 101:1999-2004
95. Miyazawa M, Nishio J, Chesebro B (1988) Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med 168:1587-1605
96. bm12. J Exp Med 153:464-469
97. Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL (2004) Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J Immunother 27:329-338
98. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54:172-178
99. Baton F, Deruyffelaere C, Chapin M, Prod'homme T, Charron D, Al-Daccak R, Alcaide-Loridan C (2004) Class II transactivator (CIITA) isoform expression and activity in melanoma. Melanoma Res 14:453-461
100. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, Suzuki H, Sasaki Y, Kanaseki T, Takamura Y, Soejima H, Urano T, Yanagihara K, Endo T, Hinoda Y, Fujita M, Hosokawa M, Sato N, Tokino T, Imai K (2004) Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23:8876-8886
101. Snell GD (1958) Histocompatibility genes of the mouse. II. Production and analysis of isogenic resistant lines. J Natl Cancer Inst 21:843-877
102. Frankel WN (1995) Taking stock of complex trait genetics in mice. Trends Genet 11:471-477
103. Chan CL, Chafai N, Rickard MJ, Dent OF, Chapuis PH, Bokey EL (2004) What pathologic features influence survival in patients with local residual tumor after resection of colorectal cancer? J Am Coll Surg 199:680-686
104. Mocellin S, Semenzato G, Mandruzzato S, Riccardo Rossi C (2004) Part II: Vaccines for haematological malignant disorders. Lancet Oncol 5:727-737
105. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF (2003) Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 82:199-206
106. w302 gene and molecular mechanisms of resistance to the spread of a radiation-induced lymphoma in a mouse mutant, Survivor-27. Radiat Biol Radioecol 40:500-505
107. Moerch U, Schrama D, Guldberg P, Seremet T, Zeuthen J, Becker JC, thor Straten P (2000) Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma. Cancer Immunol Immunother 49:426-432
108. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133
109. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218
110. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766-4772
111. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2:1
112. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-53
113. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
114. Gilboa E (1999) How tumors escape destruction and what we can do about it. Cancer Immunol Immunother 48:382-385
115. Hussain SF, Paterson Y (2005) What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother (Online) DOI: 10.1007/s00262-004-0600-2, 14 Jan 2005
116. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Osrand-Rosenberg S (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 15:2205-2211
117. Schrama D, Fuchs E, Bröcker E-B, thor Straten P, Becker JC (2002) Identical T-cell receptor transcripts in multiple melanoma metastases. Cancer Res 62:5664-5667
118. Willhauck M, Scheibenbogen C, Pawlita M, Mohler T, Thiel E, Keilholz U (2003) Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. Cancer Res 63:3483-3485
119. Levraud JP, Pannetier C, Langlade-Demoyen P, Brichard V, Kourilsky P (1996) Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor. J Exp Med 183:439-449
120. Corthay A, Lundin KU, Munthe LA, Froyland M, Gedde-Dahl T, Dembic Z, Bogen B (2004) Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol Immunother 53:759-769
121. thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J (1996) Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 98:279-284
122. Lee K-H, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA, Marincola FM (1998) Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183-4194
123. thor Straten P, Guldberg P, Grønbæk K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC (1999) In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunology 163:443-447
124. Yang J, Zimmerly S, Perlman PS, Lambovitz AM (1996) Efficient integration of an intron RNA into double-stranded DNA by reverse splicing. Nature 381:332-335
125. Kurahashi H, Shaikh TH, Hu P, Roe BA, Emanuel BS, Budarf ML (2000) Regions of genomic instability on 22q11 and 11q23 as the etiology for recurrent constitutional t(11;22). Hum Mol Genet 9:1665-1670
126. Razin SV, Ioudinkova ES, Trifonov EN, Scherrer K (2001) Non-clonability correlates with genomic instability: a case study of a unique DNA region. J Mol Biol 307:481-486
127. Durandy A (2003) Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur J Immunol 33:2069-2073
128. Wang CL, Harper RA, Wabl M (2004) Genome-wide somatic hypermutation. Proc Natl Acad Sci USA 101:7352-7356
129. Rovere-Querini P, Manfredi AA (2004) Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer. JOP 5:308-314
130. Carcelain G, Rouas-Freiss N, Zorn E, Chung-Scott V, Viel S, Faure F, Bosq J, Hercend T (1997) In situ T-cell responses in a primary regressive melanoma and subsequent metastases: a comparative analysis. Int J Cancer 72:241-247
131. Papac RJ (1998) Spontaneous regression of cancer: possible mechanisms. In Vivo 12:571-578
132. Mostoslavsky R, Alt FW (2004) Receptor revision in T cells: an open question. Trends Immunol 25:276-279
133. Mathiot C, Robin E, Gey A, Weng X, Dorval T, Pouillart P, Sastre X, Zerbib M, Hamelin JP, Salmon R et al (1992) Phenotypic and functional analysis of tumor-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. Eur J Cancer 28:345-350
134. + T cells. World J Surg 19:352-358
135. Golubic M, Budimir O, Schoepfer R, Kasahara M, Mayer WE, Figueroa F, Klein J (1987) Nucleotide sequence analysis of class II genes borne by mouse t chromosomes. Genet Res (Camb) 50:137-146
136. Falconer DS, Mackay TFC (1996) Introduction to quantitative genetics. Harlow, London
137. Bonnefoy JY (2004) Cancer vaccines. Expert Opin Ther Targets 8:521-525
138. Bubenik J (2004) MHC class I down-regulation: tumor escape from the immune surveillance? Int J Oncol 25:487-491
139. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Zur Wiesch JS, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200:1593-604
140. Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P (2005) Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol 35(2):341-351